Back to Directory

Edward Acosta

Email

Phone

Institution

University of Alabama

Address

Alabama Therapeutics CRS
Division of Clinical Pharmacology
Department of Pharmacology and Toxicology
1670 University Boulevard, VH 258
Birmingham, AL 35294-0019
United States of America

Request an Update

Affiliated Studies

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1

DAIDS Number

38953

Research Area

Therapeutics

Study Status

Withdrawn

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

38932

Research Area

Therapeutics

Study Status

Enrolling

P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity

DAIDS Number

10495

Research Area

Treatment

Study Status

Concluded

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

Show All